179 related articles for article (PubMed ID: 38150000)
1. Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation.
Trebino TE; Markusic B; Nan H; Banerjee S; Wang Z
Elife; 2023 Dec; 12():. PubMed ID: 38150000
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation.
Trebino T; Markusic B; Nan H; Banerjee S; Wang Z
bioRxiv; 2023 Sep; ():. PubMed ID: 37163002
[TBL] [Abstract][Full Text] [Related]
3. RASopathy mutations provide functional insight into the BRAF cysteine-rich domain and reveal the importance of autoinhibition in BRAF regulation.
Spencer-Smith R; Terrell EM; Insinna C; Agamasu C; Wagner ME; Ritt DA; Stauffer J; Stephen AG; Morrison DK
Mol Cell; 2022 Nov; 82(22):4262-4276.e5. PubMed ID: 36347258
[TBL] [Abstract][Full Text] [Related]
4. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
5. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes.
Park E; Rawson S; Li K; Kim BW; Ficarro SB; Pino GG; Sharif H; Marto JA; Jeon H; Eck MJ
Nature; 2019 Nov; 575(7783):545-550. PubMed ID: 31581174
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and inhibition of BRAF kinase.
Gunderwala A; Cope N; Wang Z
Curr Opin Chem Biol; 2022 Dec; 71():102205. PubMed ID: 36067564
[TBL] [Abstract][Full Text] [Related]
7. B-Raf autoinhibition in the presence and absence of 14-3-3.
Zhang M; Jang H; Li Z; Sacks DB; Nussinov R
Structure; 2021 Jul; 29(7):768-777.e2. PubMed ID: 33711246
[TBL] [Abstract][Full Text] [Related]
8. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
9. The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS.
Aramini JM; Vorobiev SM; Tuberty LM; Janjua H; Campbell ET; Seetharaman J; Su M; Huang YJ; Acton TB; Xiao R; Tong L; Montelione GT
Structure; 2015 Aug; 23(8):1382-1393. PubMed ID: 26165597
[TBL] [Abstract][Full Text] [Related]
10. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
11. Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding.
Martinez Fiesco JA; Durrant DE; Morrison DK; Zhang P
Nat Commun; 2022 Jan; 13(1):486. PubMed ID: 35078985
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
13. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ; Phung I; Potes MI; Tamanoi F
BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
[TBL] [Abstract][Full Text] [Related]
14. BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.
Röck R; Mayrhofer JE; Torres-Quesada O; Enzler F; Raffeiner A; Raffeiner P; Feichtner A; Huber RG; Koide S; Taylor SS; Troppmair J; Stefan E
Sci Adv; 2019 Aug; 5(8):eaav8463. PubMed ID: 31453322
[TBL] [Abstract][Full Text] [Related]
15. A novel phosphorylation site involved in dissociating RAF kinase from the scaffolding protein 14-3-3 and disrupting RAF dimerization.
Yu A; Nguyen DH; Nguyen TJ; Wang Z
J Biol Chem; 2023 Oct; 299(10):105188. PubMed ID: 37625591
[TBL] [Abstract][Full Text] [Related]
16. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
17. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
18. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K
Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033
[TBL] [Abstract][Full Text] [Related]
19. Analysis of RAS and drug induced homo- and heterodimerization of RAF and KSR1 proteins in living cells using split Nanoluc luciferase.
Rohrer L; Spohr C; Beha C; Griffin R; Braun S; Halbach S; Brummer T
Cell Commun Signal; 2023 Jun; 21(1):136. PubMed ID: 37316874
[TBL] [Abstract][Full Text] [Related]
20. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
